Denosumab Injection
Sponsors
Saitama Medical University, Massachusetts General Hospital, Kyoto Prefectural University of Medicine, Albert Einstein Healthcare Network, Hospital for Special Surgery, New York
Conditions
Breast CancerCharcot FootDenosumabDenosumab AllergyDiabetes MellitusOsteoporosisOsteoporosis, PostmenopausalPostmenopausal Osteoporosis
Phase 2
Phase 3
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
Active, not recruitingNCT03324932
Start: 2017-09-25End: 2027-12-31Target: 160Updated: 2023-10-06
The DENOCHARCOT Trial
RecruitingNCT04547348
Start: 2020-11-01End: 2026-10-01Target: 38Updated: 2024-08-07
Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes
NCT06154707
Start: 2024-02-01End: 2025-03-01Target: 86Updated: 2024-08-16
Phase 4
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
CompletedNCT01750086
Start: 2013-01-31End: 2014-08-31Updated: 2017-03-27
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Active, not recruitingNCT04467983
Start: 2021-02-01End: 2026-12-01Target: 70Updated: 2026-06-08
Denosumab vs Zoledronate After Vertebroplasty
CompletedNCT05598606
Start: 2021-01-12End: 2023-01-14Updated: 2023-01-18